Pharmacology of orthostatic hypotension in Parkinson's disease: From pathophysiology to management

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 3, 2004, Pages 393-403

  Pathak, Atul ^a   Senard, Jean Michel ^a  

^a INSERM   (France)

Author keywords

Fludrocortisone; Midodrine; Nonpharmacological measures; Orthostatic hypotension; Peripheral autonomic failure

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ANTIPARKINSON AGENT; BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; CAFFEINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; DESMOPRESSIN; DIHYDROERGOTAMINE MESILATE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT ALKALOID; ERYTHROPOIETIN; ETILEFRINE; FLUDROCORTISONE; LEVODOPA; METOCLOPRAMIDE; MIDODRINE; MONOAMINE OXIDASE INHIBITOR; OCTREOTIDE; PHENYLPROPANOLAMINE; PROAMATIN; PYRIDOSTIGMINE; SELEGILINE; THREO 3,4 DIHYDROXYPHENYLSERINE; UNINDEXED DRUG; YOHIMBINE;

ABDOMINAL PAIN; ALOPECIA; ANKLE EDEMA; ANXIETY DISORDER; BRADYCARDIA; CHILL; CLINICAL TRIAL; DIARRHEA; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DOPAMINERGIC SYSTEM; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG METABOLISM; DRUG STRUCTURE; DYSESTHESIA; DYSURIA; FIBROSIS; GALLBLADDER DISEASE; HEADACHE; HEART FAILURE; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; MORBIDITY; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERIPHERAL VASCULAR DISEASE; POLYURIA; POSITRON EMISSION TOMOGRAPHY; PRURITUS; REVIEW; SLEEP DISORDER; TACHYCARDIA; THROMBOSIS; TREMOR; VASOCONSTRICTION;

ANTIPARKINSON AGENTS; AUTONOMIC NERVOUS SYSTEM DISEASES; BLOOD VOLUME; EFFERENT PATHWAYS; HUMANS; HYPOTENSION, ORTHOSTATIC; PARKINSON DISEASE; POSTPRANDIAL PERIOD; VASOCONSTRICTOR AGENTS;

EID: 2542497935     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.3.393     Document Type: Review

References (72)

1. Rutan GH, Hermanson B, Bild DE, Kittner SJ, LaBaw F, Tell GS. Orthostatic hypotension in the older adults. The cardiovascular health study. Hypertension 19, 508-519 (1992).
2. Raïha I, Luutonen S, Piha J, Seppanen A, Toikka T, Sourander L. Prevalence predisposing factors and prognosis importance of postural hypotension. Arch. Intern. Med. 155, 930-935 (1995).
3. Elmstahl S, Rosen I. Postural hypotension and EEG variables predict cognitive decline: results from a 5-year follow-up of healthy elderly women. Dement. Geriatr. Cogn. Disord. 8, 180-187 (1997).
4. Eigenbrodt ML, Rose KM, Couper DJ, Arnett DK, Smith R, Jones D. Orthostatic hypotension as a risk factor for stroke. The Atherosclerosis Risk in Communities (ARIC) study, 1987-1996. Stroke 31, 2307-2313 (2000).
5. Rose KM, Tyroler HA, Nardo CJ et al. Orthostatic hypotension and the incidence of coronary heart disease: the Atherosclerosis Risk in Communities Study. Am. J. Hypertens. 13, 571-578 (2000).
6. Masaki KH, Schatz IJ, Burchfiel CM et al. Orthostatic hypotension predicts mortality in elderly men. The Honolulu heart program. Circulation 98, 2290-2295 (1998).
7. Luukinen H, Koski K, Laippala P, Kivela SL. Prognosis of diastolic and systolic orthostatic hypotension in older persons. Arch. Intern. Med. 159, 273-280 (1999).
8. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Neurology 46, 1470 (1996).
9. Korczyn AD. Autonomic nervous system disturbances in Parkinson's disease. In: Advances in Neurology: Parkinson's Disease: Anatomy Pathology and Therapy. Streifler MB, Korczyn AD, Melamed E, Youdim MBH (Eds). Raven Press, NY, USA, 53, 463-468 (1990).
10. Bannister R, Mathias CJ. Introduction and classification of autonomic disorders. In: A Textbook of Clinical Disorders of the Autonomic Nervous System. Mathias CJ, Bannister R (Eds). Oxford University Press, Oxford, UK 17-22 (1999).
11. Gilman S, Low PA, Quinn N et al. Consensus statement on the diagnosis of multiple system atrophy. J. Auton. Nerv. Syst. 74, 189-192 (1998).
12. van Dijk JG, Haan J, Zwinderman K, Kremer B, van Hilten BJ, Roos RA. Autonomic nervous system dysfunction in Parkinson's disease: relationship with age, medication, duration and severity. J. Neurol. Neurosurg. Psychiatry 56, 1090-1095 (1993).
13. Wenning GK, Scherfler C, Granata R et al. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed Parkinsonian syndromes: a clinicopathological study. J. Neurol. Neurosurg. Psychiatry 67, 620-623 (1999).
14. Senard JM, Raï S, Lapeyre-Mestre M. Prevalence of orthostatic hypotension in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 63, 584-589 (1997).
15. Bonuccelli U, Lucetti C, Del Dotto P et al. Orthostatic hypotension in de novo Parkinson's disease. Arch. Neurol. 60, 1400-1404 (2003).
16. Chaudhuri KR, Ellis C, Love-Jones S et al. Postprandial hypotension and Parkinsonian state in Parkinson's disease. Mov. Disord 12, 877-884 (1997).
17. Senard JM, Chamontin B, Rascol A, Montastruc JL. Ambulatory blood pressure in patients with Parkinson's disease without and with orthostatic hypotension. Clin. Auton. Res. 2, 99-104 (1992).
18. Wakabayashi K, Takahashi H, Ohama E, Takeda S, Ikuta F. Lewy bodies in the visceral autonomic nervous system in Parkinson's disease. In: Advances in Neurology. Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y (Eds). Raven Press, NY, USA, 609-612 (1993).
19. Golstein DS, Holmes C, Sharabi Y, Brentzel S, Eisenhofer G. Plasma levels of catechols and metanephrines in neurogenic orthostatic hypotension. Neurology 60, 1327-1332 (2003).
20. Kimber JR, Watson L, Mathias CJ. Distinction of Parkinson's disease from multiple system atrophy by stimulation of growth-hormone release with clonidine. Lancet 349, 1877-1881 (1997).
21. Senard JM, Rascol O, Durrieu G et al. Effects of yohimbine on plasma catecholamine levels in orthostatic hypotension related to Parkinson's disease or multiple system atrophy. Clin. Neuropharmacol. 16, 70-76 (1993).
22. 123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology 53, 1020-1025 (1999).
23. Takatsu H, Nishida H, Matsuo H et al. Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. J. Nucl. Med. 41, 71-77 (2000).
24. Courbon F, Brefel-Courbon C, Thalamas C et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov. Disord. 18, 890-897 (2003).
25. Goldstein DS. Dysautonomia in Parkinson's disease: neurocardiogical abnormalities. Lancet Neurol. 2, 669-676 (2003).
26. Lee EA, Kim BJ, Lee WY. Diagnosing multiple system atrophy with greater accuracy: combined analysis of the clonidine-growth hormone test and external anal sphincter electromyography. Mov. Disord. 6, 1242-1247 (2002).
27. Verhaeverbeke I, Mets T. Drug-induced orthostatic hypotension in the elderly. Avoiding its onset. Drug Safety 17, 105-118 (1997).
28. Turkka J, Suominen K, Tolonen U, Sotaniemi K, Myllyla VV. Selegiline disminishes cardiovascular autonomic responses in Parkinson's disease. Neurology 48, 662-667 (1997).
29. Lyytinen J, Sovijärvi A, Kaakkola S, Gordin A, Teräväinen H. The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease. Clin. Neuropharmacol. 24, 50-57 (2001).
30. Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch. Neurol. 57, 1461-1463 (2000).
31. Parker SG, Raval P, Yeulet S, Eden RJ. Tolerance to peripheral but not central, effects of ropinirole, a selective dopamine D2-like receptor agonist. Eur. J. Pharmacol. 265, 17-26 (1991).
32. Montastruc JL, Llau ME, Senard JM, Tran MA, Rascol O, Montastruc P. A study of tolerance to apomorphine. Br. J. Pharmacol, 117, 781-786 (1996).
33. Bannister R, Mathias CJ. Management of postural hypotension. In: A Text Book of Clinical Disorders of the Autonomic Nervous System. Mathias CJ, Bannister R (Eds). Oxford University Press, Oxford, UK, 342-356 (1999).
34. Senard JM, Rascol O, Rascol A, Montastruc JL. Lack of yohimbine effect on ambulatory blood pressure recording: a double-blind cross-over trial in Parkinsonians with orthostatic hypotension. Fundam. Clin. Pharmacol. 7, 465-470 (1993).
35. Lopes de Faria S, Zanella MT, Andriolo A, Ribeiro AB, Chacra AR. Peripheral dopaminergic blockade for the treatment of diabetic orthostatic hypotension. Clin. Pharmacol. Ther. 44, 670-674 (1988).
36. Montastruc JL, Chamontin B, Senard JM, Rascol A. Domperidone in the management of orthostatic hypotension. Clin. Neuropharmacol. 8, 191-192 (1985).
37. Capria A, Attanasio A, Quatrana M et al. Cardiovascular effects of lisuride continuous intravenous infusion in fluctuating Parkinson's disease. Clin. Neuropharmacol. 12, 331-338 (1989).
38. Biaggioni I, Robertson D. Endogenous restoration of noradrenaline by precursor therapy in dopamine-β-hydroxylase deficiency. Lancet 21, 1170-1175 (1987).
39. Freeman R, Landsberg L, Young J. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine. A randomized, placebo-controlled, crossover trial. Neurology 53, 2151-2157 (1999).
40. Mathias CJ, Senard JM, Braune S et al. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multinational, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin. Auton. Res. 11, 235-242 (2001).
41. Kaufmann H, Saadia D, Voustianiouk A et al. Noradrenaline precursor therapy in neurogenic orthostatic hypotension. Circulation 108, 724-728 (2003).
42. Park KH, Long JP, Cannon JG. Reversal of antihypertensive agent-induced postural hypotension with physostigmine. Arch. Int. Pharmacodyn. 311, 155-165 (1991).
43. Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J. Neurol. Neurosurg. Psychiatry 74, 1294-1298 (2003).
44. Miller E, Wiener L, Bloomfield D. Etilefrine in the treatment of levodopa-induced orthostatic hypotension. Arch. Neurol. 29, 99-103 (1973).
45. Biaggioni I, Onrot J, Stewart CK, Robertson D. The potent pressor effect of phenylpropanolamine in patients with autonomic impairment. JAMA 258, 236-239 (1987).
46. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary suplements containing ephedra alkaloids. N. Engl. J. Med. 343, 1833-1838 (2000).
47. Kernan WN, Viscoli CM, Brass LM et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N. Engl. J. Med. 343, 1826-1832 (2000).
48. McClellan KJ, Wiseman LR, Wilde MI. Midodrine: a review of its therapeutical use in the management of orthostatic hypotension. Drugs Aging 12, 76-86 (1998).
49. Jankovic J, Gilden JL, Hiner BC et al. Neurogenic orthostatic hypotension: a double-blind placebo-controlled study with midodrine. Am. J. Med. 95, 38-48 (1993).
50. Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine versus placebo in neurogenic orthostatic hypotension. JAMA 277, 1046-1051 (1997).
51. Desboeuf K, Senard JM, Pavy-Le-Traon A et al. Clinical practice survey of midodrine prescribing in a universitary hospital. Therapie 55, 613-617 (2000).
52. Ten Harkel AD, van Lieshout JJ, Weling W. Treatment of orthostatic hypotension with sleeping in the head-up tilt position and in combination with fludrocortisone. J. Intern. Med. 232, 139-145 (1992).
53. Hoehn MM. Levodopa-induced postural hypotension. Treatment with fludrocortisone. Arch. Neurol. 32, 50-51 (1975).
54. Hakamäki T, Rajala T, Lehtonen A. Ambulatory 24-hour blood pressure recordings in patients with Parkinson's disease with or without fludrocortisone. Int. J. Clin. Pharmacol. Ther. 36, 367-370 (1998).
55. Biaggioni I, Robertson D, Krantz S, Jones M, Haile V. The anemia of primary autonomic failure and its reversal with recombinant erythropoietin. Ann. Int. Med. 121, 181-186 (1994).
56. Hoeldtke RD, Streeten DHP. Treatment of orthostatic hypotension with erythropoietin. N. Engl. J. Med. 329, 611-615 (1993).
57. Perera L, Isola L, Kaufmann H. Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure. Clin. Auton. Res. 5, 211-213 (1995).
58. Nair B, Leitch J. Erythropoietin treatment for postural hypotension from autonomic dysfunction. Aust. NZ. J. Med. 26, 859-860 (1996).
59. Mathias CJ, Fosbraey P, da Costa DF, Thornley A, Bannister R. The effect of desmopressin on nocturnal polyuria, overnight weight loss and morning postural hypotension in patients with autonomic failure. Br. Med. J. 293, 353-354 (1986).
60. Onrot J, Goldberg MR, Biaggioni I, Hollister AS, Kincaid D, Robertson D. Haemodynamic and humoral effect of caffeine in autonomic failure: therpaeutic implications for postprandial hypotension. N. Engl. J. Med. 313, 549-554 (1985).
61. Lipsitz LA, Jansen RWMM, Connelly CM, Kelley-Gagnon HM, Parker AJ. Haemodynamic and neurohumoral effects of caffeine in elderly patients with symptomatic postprandial hypotension: a double-blind, randomized, placebo-controlled study. Clin. Sci. 87, 259-267 (1994).
62. Bordet R, Benhadjali J, Libersa. C, Destée A. Octreotide in the management of orthostatic hypotension in multiple system atrophy: pilot trial of chronic administration. J. Clin. Neuropharmacol. 17, 380-383 (1994).
63. Hoeldtke RD, Horvath GG, Bryner KD, Hobbs GR. Treatment of orthostatic hypotension with midodrine and octreotide. J. Clin. Endocrinol. Meth. 83, 339-343 (1998).
64. Mathias CJ, Kimber JR. Treatment of postural hypotension. J. Neurol. Neurosurg. Psychiatry 65, 285-289 (1998).
65. Henry R, Rowe J, O'Mahony D. Haemodynamic analysis of efficacy of compression hosiery in elederly fallers with orthostatic hypotension. Lancet 354, 45-46 (1999).
66. Bouvette CM, McPhee BR, Opfer-Gehrking TL, Low PA. Role of physical countermaneuvers in the management of orthostatic hypotension: efficacy and biofeedback augmentation. Mayo Clin. Proc. 71, 847-853 (1996).
67. Ten Harkel ADJ, van Lieshout JJ, Wieling W. Effects of leg muscle pumping and tensing on orthostatic arterial pressure: a study in normal subjects and patients with autonomic failure. Clin. Sci. 87, 553-558 (1994).
68. Fahn S, Elton RL, UPDRS program members. Unified Parkinson's disease rating scale. In: Recent Developments in Parkinson's Disease, Vol. 2. Fahn S, Marsden CD, Goldstein M, Caine DB (Eds). McMillan Healthcare Information, NJ, USA, 153-163 (1987).
69. Movement disorder Society Task Force on rating scales for Parkinson's disease. The unified Parkinson's disease rating scale (UPDRS): status and recommendations. Mov. Disord. 18, 738-750 (2003).
70. Raffaele R, Vecchio I, Giammusso B, Morgia G, Brunetto MB, Rampello L. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. Eur. Urol. 41, 382-386 (2002).
71. Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J. Neurol. Neurosurg. Psychiatry 71, 371-374 (2001).
72. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 359, 1589-1598 (2002).